Lercanidipino Ratiopharm (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L-type calcium channels in arterial smooth muscle. This blocks calcium entry, causing the vessels to relax and dilate, which decreases peripheral vascular resistance and results in a reduction of systemic blood pressure.

The appropriate dose of Lercanidipino Ratiopharm is determined by the prescribing clinician based on the patient’s blood pressure, age, renal and hepatic function, and concomitant medications. The prescriber will select the starting dose and any subsequent adjustments.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and the necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, offering potent vasodilation with a relatively low effect on heart rate. Compared with agents such as amlodipine, it has a similar efficacy profile but may differ in pharmacokinetic properties and side‑effect frequency, which the prescriber will consider.

Store the tablets at ambient temperature, preferably below 25 °C, in their original packaging. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Lercanidipino Ratiopharm is taken orally, usually once daily. It can be swallowed with or without food, but patients should follow the specific instructions provided by their healthcare professional.

Serious risks include severe hypotension, angioedema, myocardial infarction, and cardiac arrhythmias. Patients should be advised to seek immediate medical attention if they experience symptoms such as sudden dizziness, swelling of the face or throat, chest pain, or irregular heartbeat.

Lercanidipino Ratiopharm is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation, as well as in individuals with severe aortic stenosis or uncontrolled heart failure. The prescriber should evaluate each patient’s medical history before initiating therapy.